INVVY
Indivior PLC · Healthcare
21.85
0.00%(+0.00)
Close PriceLast Updated: — ET
52W L: $14.7652W H: $75.65
INVVY NEWS
zacks.com
10h ago
How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99%
The consensus price target hints at a 46% upside potential for Indivior Pharmaceuticals Inc. (INDV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
globenewswire.com
1d ago
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.
seekingalpha.com
Mar 30
Indivior: Still Attractive After FY25 Earnings Beat
Indivior has rallied over 300% since 2024 lows, driven by Sublocade market share stability, cost controls, and shareholder activism. INDV remains a 'buy' at a $3.7bn market cap, with management targeting 8% Sublocade sales growth in 2026 and 48% adj. EBITDA margins. Valuation is attractive at sub-10x NTM EV/EBITDA and a 10% FCF yield, with a $400m buyback approved for 2026–2027.
zacks.com
Mar 25
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV)
The heavy selling pressure might have exhausted for Indivior Pharmaceuticals Inc. (INDV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
globenewswire.com
Mar 12
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on March 17, 2026, subject to customary closing conditions.
globenewswire.com
Mar 12
Indivior Announces Proposed Convertible Senior Notes Offering
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Indivior also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $60,000,000 principal amount of notes.